SCHEMBL5716675

SCHEMBL5716675

COc1cnc2c(c1)cc(C(=O)c1ccccc1OC)n2S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC7 Q8WUI4 2/20 0.43
HDAC2 Q92769 2/20 0.43
HDAC10 Q969S8 2/20 0.43
HDAC11 Q96DB2 2/20 0.43
HDAC8 Q9BY41 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
HDAC9 Q9UKV0 2/20 0.43
HDAC5 Q9UQL6 2/20 0.43
MAPT P10636 3/20 0.42
POLB P06746 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HTT P42858 2/20 0.39
HSD11B1 P28845 1/20 0.39
HTR6 P50406 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5716716 0.92 HTT (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5716689 0.86 TUBB4A (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5716750 0.85 MAPT (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5716762 0.84 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL5716692 0.80 HTT (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7065741 0.79 LMNA (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1683406 0.79 HTR6 (0.46) MAPTPOLBKMT2ALMNAALDH1A1
SCHEMBL23147752 0.78 NOD2 (0.47) MAPTKMT2ALMNAL3MBTL1MEN1
SCHEMBL22494274 0.77 HTR6 (0.44) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1958748 0.77 FKBP1A (0.38) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276720-B1 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS BAXTER HEALTHCARE SA (CH) 2006-12-20 EP disclosed
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents BAXTER ONCOLOGY GMBH 2003-08-21 US disclosed
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents BECKERS THOMAS (DE) 2002-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158216-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT HDAC3 309/4885HDAC4 729/4885HDAC1 261/4885
US-20020091124-A1 2-acyl indole derivatives and their use as antitumor agents IDO1, IDO2, INMT HDAC3 309/4885HDAC4 729/4885HDAC1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.